

1 **Putative β -barrel outer membrane proteins of the bovine digital**
2 **dermatitis-associated treponemes: identification, functional**
3 **characterisation and immunogenicity.**

4
5 Staton, G.J.¹, Carter, S.D.¹, Ainsworth, S.^{1¶}, Mullin, J.¹, Smith R. F.² and Evans, N.J.¹

6 1. Department of Infection Biology, Institute of Infection & Global Health, University of
7 Liverpool, Leahurst Campus, Chester High Road, Neston, Cheshire, UK, CH64 7TE

8

9 2. Department of Livestock Health and Welfare, Institute of Veterinary Science,
10 University of Liverpool, Leahurst Campus, Chester High Road, Neston, Cheshire, UK,
11 CH46 7TE

12

13 [¶]Current affiliation: Centre for Snakebite Research and Interventions, Liverpool School of
14 Tropical Medicine, Pembroke Place, Liverpool, UK, L3 5QA.

15

16 **Corresponding author:** Evans N.J., Department of Infection Biology, Institute of Infection &
17 Global Health, University of Liverpool, Leahurst Campus, Chester High Road, Neston,
18 Cheshire, UK, CH64 7TE. Email: evansnj@liverpool.ac.uk

19

20 **Running Title:** β -barrel proteins of digital dermatitis-associated treponemes

21

22 **Abbreviations:** BDD, bovine digital dermatitis; OMP, outer membrane protein

23

24 **Word count:** 5846

25

26

27

28 **Abstract.**

29 Bovine Digital Dermatitis (BDD), an infectious disease of the bovine foot with a predominant
30 treponemal aetiology, is a leading cause of lameness in dairy and beef herds worldwide. BDD
31 is poorly responsive to antimicrobial therapy and exhibits a relapsing clinical course; an
32 effective vaccine is therefore urgently sought. Using a 'reverse vaccinology' approach, the
33 present study surveyed the genomes of the three BDD-associated *Treponema* phylogroups
34 for putative β -barrel outer membrane proteins and considered their potential as vaccine
35 candidates. Selection criteria included the presence of a signal peptidase I cleavage site, a
36 predicted β -barrel fold and cross-phylogroup homology. Four candidate genes were
37 overexpressed in *Escherichia coli* BL21 (DE3), refolded and purified. Consistent with their
38 classification as β -barrel OMPs, circular dichroism spectroscopy revealed the adoption of a
39 predominantly β -sheet secondary structure. These recombinant proteins, when screened for
40 their ability to adhere to immobilised ECM components, exhibited a diverse range of ligand
41 specificities. All four proteins specifically and dose-dependently adhered to bovine fibrinogen.
42 One recombinant protein was identified as a candidate diagnostic antigen (disease specificity,
43 75%). Finally, when adjuvanted with aluminium hydroxide and administered to BDD-naïve
44 calves using a prime-boost vaccination protocol, these proteins were immunogenic, eliciting
45 specific IgG antibodies. In summary, we present the description of four putative treponemal
46 β -barrel OMPs that exhibit the characteristics of multispecific adhesins. The observed
47 interactions with fibrinogen may be critical to host colonisation and dissemination and it is
48 hypothesised that vaccination-induced antibody blockade of these interactions will impede
49 treponemal virulence and thus be of therapeutic value.

50

51

52

53

54

55

56

57

58

59

60

61 **Introduction.**

62 Bovine digital dermatitis (BDD) is a painful, ulcerative disease of the bovine foot and a
63 significant cause of lameness in dairy cattle. Clinically, BDD presents as a malodorous, focally-
64 inflamed, circumscribed lesion of raised hyperkeratotic skin localised to the plantar/palmer
65 aspect of the interdigital cleft, on or adjacent to the coronary band (1, 2). BDD is now
66 considered to be the most common infectious cause of lameness in dairy cattle herds in the
67 northern hemisphere and one of the most significant challenges to farm animal welfare.
68 Moreover, the economic burden to the dairy industry resulting from production losses is
69 considerable (3). In the UK, BDD is endemic, affecting an estimated 79% of UK dairy farms (4),
70 and emergence of BDD in beef herds has also been recently described (5, 6). In addition, a
71 new variant (contagious ovine digital dermatitis), noted for its particularly severe
72 presentation in sheep, continues to spread through the UK's national flock (7, 8). This disease
73 therefore represents an additional and growing challenge to global food security.

74 A substantial body of evidence supports the involvement of multiple *Treponema* spp. at
75 various stages of BDD lesion development (9–12). Three treponeme taxa in particular have
76 been consistently isolated from lesion biopsy material from cases in the US and the UK,
77 namely the *Treponema medium* phylogroup, the *Treponema phagedenis* phylogroup and
78 *Treponema pedis* (13, 14). The presence of these organisms deep within the lesion (15, 16),
79 their clear association with necrotic changes in infected tissue (17), a failure to isolate these
80 organisms from the feet of healthy animals (12, 18) and a disease-associated, specific IgG
81 antibody response to these organisms (19–23) strongly implies an aetiopathogenic role in
82 BDD.

83 Treponemes are gram-stain-negative bacteria exhibiting a spiral morphology and consist of
84 an outer membrane (OM) that surrounds the axial filaments and the protoplasmic cylinder
85 (24). The OM of these extracellular pathogens is a feature of considerable interest, given its
86 surface exposure and the subsequent involvement of its components in host-pathogen
87 interactions. Adhesins embedded in the OM play a critical role in bacterial cytoadherence to
88 the host during colonisation. The host extracellular matrix (ECM) is an important adherence
89 target for pathogenic microorganisms during the primary stages of infection. Previous studies
90 investigating the ECM binding capacity of the two most relevant human pathogenic species,
91 *T. pallidum* sub. *pallidum*, the causative agent of syphilis, and *Treponema denticola*, a key
92 member of the polymicrobial consortium implicated in periodontal disease, reported specific
93 treponemal cell adherence to a range of immobilised ECM components, including fibronectin,
94 laminin, fibrinogen and collagen (25, 26). Subsequently, a growing number of adhesins are
95 being identified and investigated to characterise the molecular basis of physical host-
96 pathogen interactions (27–35). However, the fastidious nature of the BDD-associated
97 treponemes has precluded any detailed characterisation of the OM components likely to
98 promote such interactions. Employing recently available BDD-associated treponeme genome
99 sequences, we sought to identify novel β -barrel OMP-encoding genes and characterise the
100 function of the recombinantly expressed OMPs in ECM binding assays.

101 **METHODS.**

102 **Ethical approval.**

103 All experimental work involving animals was covered by a UK Home Office Project License PPL
104 70/8330.

105 ***In silico* identification of Outer Membrane Proteins (OMPs).**

106 Previously generated and annotated representative genomes of the three BDD treponemes,
107 *T. medium* T19 (Accession CP027017), *T. phagedenis* T320A (Accession CP027018) and *T. pedis*
108 T3552B^T (Accession CP045760) were subjected to *in silico* analysis to identify putative OMPs
109 via prediction of encoded β -barrel structural motifs. Putative Coding Sequence (CDS) features
110 for each genome were translated to their amino acid sequences using Artemis (36). All
111 translated *T. medium* T19 CDS features were analysed for the presence of a signal peptidase
112 I cleavage site using SignalP 4.1 (37). Sequences predicted to harbour a signal peptide were
113 further scrutinised for signatures of β -barrel tertiary structure using three β -barrel prediction
114 programs (BOMP (38), TMBETA-NET (39) and PRED-TMBB (40)). All *T. medium* T19 CDS
115 features which were predicted to code a β -barrel tertiary structured protein by at least one
116 of the β -barrel prediction programs were retained. Homologues of putative *T. medium* T19
117 OMPs were identified in *T. phagedenis* T320A and *T. pedis* T3552B^T genomes using a
118 combination of a Markov cluster algorithm (41) and BLAST (42) and their OMP predictions
119 verified independently. Putative OMP sequences which were conserved in all three genomes
120 were examined for predicted adhesin functionality using SPAAN (43) and their tertiary
121 structures modelled using I-TASSER (44).

122 **Cloning and expression of candidate antigens.**

123 *T. medium* T19, *T. phagedenis* T320A and the *T. pedis* T3552B^T, isolated previously from BDD
124 lesion biopsies (12, 14) and cryopreserved in 10% (v/v) glycerol at -80 °C, were cultured as
125 described previously (12). Genomic DNA (gDNA) was extracted from the treponeme cultures
126 at late exponential phase using Chelex[®] 100 resin (Bio-Rad Laboratories Ltd, Hemel
127 Hempstead, UK) according to a previously described method (45). The Gateway System (Life

128 Technologies, Paisley, UK) was utilised for gene cloning and expression. Putative OMP
129 sequences, lacking their signal peptide sequences, were amplified from the gDNA using high-
130 fidelity Phusion polymerase (Thermo Scientific, Hemel Hempstead, UK) in accordance with
131 manufacturer instructions. Primers (Table 1) for amplification contained CACC overhangs to
132 facilitate entry cloning. A well-characterised OMP (OmpL1) from *Leptospira interrogans*
133 serovar *Copenhageni* strain M20 was selected (46–48) and produced as a recombinant
134 protein control.

135 Amplified putative OMPs were inserted into the Gateway entry plasmid pENTR™/D-TOPO™
136 (Life Technologies, Paisley, UK) in accordance with the manufacturer's instructions prior to
137 chemical transformation into *Escherichia coli* Top10 cells. Positive transformants were
138 selected on LB agar plates containing kanamycin (50 µg/ml) and plasmid DNA from successful
139 transformants isolated using the Qiagen Plasmid MiniPrep Kit (Qiagen, Manchester, UK).
140 Successful amplicon insertion was confirmed using EcoRV restriction digest analysis
141 (ThermoFisher, Horsham, UK). Inserts were thereafter cloned into the Gateway expression
142 vector, pDEST™17, using a site-directed integration reaction in accordance with the
143 manufacturer's instructions (Life Technologies, Paisley, UK) prior to chemical transformation
144 into DH5α *E. coli*. Positive transformants were selected on LB agar plates containing ampicillin
145 (100 µg/ml) and the plasmid DNA isolated as previously described. pDEST™17-gene
146 constructs verified by EcoRI endonuclease restriction digest analysis and Sanger sequencing
147 (Source Bioscience, Nottingham, UK).

148 **Protein expression, refolding and purification**

149 All protein expression was performed in *E. coli* BL21 DE3 (Life Technologies, Paisley, UK). *E. coli*
150 BL21 DE3 cultures were grown at 37°C with shaking in LB medium (2 L) containing ampicillin

151 (100 µg/ml), until the OD₆₀₀ was 0.8-1. Protein expression was induced by the addition of 1
152 mM IPTG (Sigma Aldrich, Gillingham, UK). Cultures were grown for a further 4-5 hours and
153 cells harvested by centrifugation (3500 x g, 4°C, 10 mins). *E. coli* BL21 DE3 cell pellets were
154 re-suspended in 50 mM Tris-HCl pH 7.9 (20ml per 10 g wet cell weight) containing lysozyme
155 (5 mg/g wet cell weight) (Sigma Aldrich, Gillingham, UK) and incubated on ice for 30 min prior
156 to cellular disruption using a micro-sonicator tip (Soniprep-150, MSE, London, UK). Inclusion
157 bodies (IB) containing recombinant proteins were subsequently harvested by centrifugation
158 (10000 x g, 4°C, 30 mins). IB pellets were re-suspended in 150 ml of IB detergent buffer (4%
159 (v/v) Tergitol™ 15-S-9 (Sigma-Aldrich, Dorset, UK), 50 mM Tris HCl, pH 7.9) with rapid stirring
160 for a minimum of two hours, washed twice in 150 ml IB wash buffer (50 mM Tris HCl, pH 7.9)
161 and re-suspended in solubilisation buffer (6M Guanidine hydrochloride, 50 mM Tris-HCl pH
162 7.9 and 1 mM EDTA; 40 ml per 500 mg of IB) for 1 hour with constant agitation. The
163 suspension was centrifuged (10, 000 x g, 4°C, 30 mins) to remove insoluble material.
164 Recombinant protein refolding was performed by rapid dilution (49) into refolding buffer (250
165 mM NaCl, 50 mM Tris-HCl pH 7.9, 5% N,N-Dimethyldodecylamine N-oxide solution (LDAO;
166 Sigma-Aldrich, Dorset UK)) and subsequently dialysed against 10 volumes of dialysis buffer
167 (250 mM NaCl, 50 mM Tris-HCl pH 7.9, 0.1% LDAO). Refolded, recombinant proteins were
168 purified by standard immobilised metal affinity chromatography (50), sterilised through a 0.2
169 µM filter and stored at -80°C. The purity of the recombinant proteins was assessed by SDS-
170 PAGE.

171 **Evaluation of secondary structure.**

172 *Heat modifiability.* The sensitivity of the recombinant proteins to denaturation upon heating
173 was determined by comparing the electrophoretic mobility of the refolded recombinant

174 proteins prepared in SDS sample buffer without reducing agent (100mM Tris-HCl [pH 6.8] 4%
175 (w/v) SDS, 0.2% (w/v) bromophenol blue, 20 % (v/v) glycerol) and either incubated at ambient
176 temperature for 10 minutes or heated to 100°C for 10 minutes prior to SDS-PAGE analysis, as
177 described previously (51).

178 *Circular dichroism (CD) spectroscopy.* Far UV CD spectroscopy was performed using a Jasco J-
179 810 spectropolarimeter (Japan Spectroscopic, Tokyo, Japan), equipped with a Peltier unit for
180 temperature control. Spectra were measured from 190 to 260 nm using 1-mm path length
181 cell at intervals of 0.5-nm and presented as an average of three scans. Spectra were analysed
182 by Beta Structure Selection (BestSel) software (<http://bestsel.elte.hu/>) (52) to calculate the
183 percentage secondary structure content from the ellipticity experimental data.

184 **Evaluation of immunogenicity during natural infection.**

185 *Cattle sera*

186 An ELISA was performed to investigate systemic IgG seroreactivity to the putative OMPs in
187 blood samples collected from cows naturally infected with BBD. Sera from sixteen adult
188 Holstein-Friesian cows with a recent (<6 month) history of BBD, were collected from a dairy
189 herd situated in Cheshire, UK. Similarly, sera from 5 healthy adult Holstein-Friesian cows were
190 collected from a closed dairy herd situated in Monmouthshire, UK, and were included as a
191 control group. In all cases, whole blood was collected from the coccygeal vein. Following
192 clotting and centrifugation, the serum fraction was harvested and stored at -20°C for
193 serological assessment.

194 *Serological ELISA*

195 Non-activated, 96-well microtitre plates (Microplate Immulon 2HB, Thermo Scientific, Hemel
196 Hempstead) were coated with a single recombinant protein (5 µg/ml) in PBS (pH 7.2) and
197 incubated for 1 hour (37°C) and overnight (4°C). Unbound antigen was removed by washing
198 with PBST (PBS-Tween 20; 0.05%). All sera were diluted 1/100 in PBST and pipetted into ELISA
199 plate wells in duplicate and incubated for 1 hour (37°C). Wells were washed as before and
200 incubated for 1 hour (37°C) with 100 µl monoclonal mouse anti-bovine immunoglobulin class
201 G subclass 1 (IgG1) antibody, clone IL-A60 (BioRad, Hemel Hempstead, UK) or monoclonal
202 mouse anti-bovine immunoglobulin class G subclass 2 (IgG2) antibody, clone IL-A2 (BioRad,
203 Hemel Hempstead, UK), diluted 1:1000. To ensure adherence of the antigen to the plate, 100
204 µl of mouse monoclonal anti-polyhistidine antibody, clone HIS-1 (Sigma-Aldrich, Dorset, UK),
205 diluted 1:2000 in PBST, was added to recombinant control wells. Following washing, wells
206 were incubated with 100 µl of horse-radish peroxidase (HRP)-conjugated goat anti-mouse IgG
207 antibodies (Sigma-Aldrich, Dorset, UK), diluted 1:10000 in PBST for 1 hour (37°C). Following
208 washing, the presence of HRP-conjugated goat anti-mouse IgG antibodies was detected by
209 the addition of 100 µl of the HRP substrate, 3,3',5,5'-Tetramethylbenzidine (TMB) (Sigma-
210 Aldrich, Dorset, UK). The reaction was terminated after ~20 minutes by the addition of 100 µl
211 0.5 M hydrochloric acid. The optical density (OD) of each well was read at 450 nm using a
212 microplate reader (Multiskan EX; Thermo Fisher Scientific, Loughborough, UK). All data was
213 processed and analysed using GraphPad Prism 5 (GraphPad, San Diego, CA). In order to
214 classify results as positive or negative, an ELISA OD value of less than or equal to the mean
215 plus 3 standard deviations of the control sera was considered to be non-reactive (53).

216 **Evaluation of adhesin function.**

217 *ECM macromolecules.*

218 All ECM macromolecules were purchased from Sigma Aldrich (Dorset, UK), and prepared from
219 the following sources: Collagen I from bovine skin; elastin from bovine neck filament;
220 fibrinogen from bovine plasma; heparan sulphate from bovine kidney; chondroitin sulphate
221 from bovine cartilage; laminin-1 from the basement membrane of Engelbreth-Holm-Swarm
222 mouse sarcoma.

223 *ECM-binding ELISA.*

224 An ELISA was performed to screen the recombinant proteins for their ability to attach to
225 individual ECM macromolecules using a previously described method (54). Briefly, Immulon
226 2HB plates (ThermoFisher, Horsham, UK) were coated with 5 µg/ml of the ECM component
227 or the negative control protein (BSA) by incubation for 1 hour at 37°C and overnight at 4°C,
228 washed with PBS containing 0.05% Tween 20 (PBST) and blocked with a 1% (w/v) BSA
229 solution. Recombinant proteins, diluted in PBST, were added at 10 µg/ml to screen for ECM
230 binding activity and a range of concentrations (from 0 to 6 µM) to determine the dose-
231 dependency of these binding interactions. Following incubation, bound recombinant proteins
232 were detected by addition of mouse monoclonal anti-polyhistidine IgG antibody (Sigma-
233 Aldrich, Dorset, UK), diluted 1:2000, before proceeding as described before. K_D values were
234 estimated from curves fitted by non-linear regression analysis in GraphPad Prism v. 5, using
235 the following equation: $K_D = (A_{max} [protein])/A - [protein]$, where A is the absorbance at a
236 given protein concentration, A_{max} is the maximum plate reader absorbance (when the
237 equilibrium is reached), [protein] is the protein concentration and K_D is the dissociation
238 equilibrium constant (55, 56).

239 *Far-western blotting.*

240 A far-western blotting technique was employed to further characterise the specific binding
241 interactions between the recombinant proteins and bovine fibrinogen (57). To dissociate
242 native bovine fibrinogen into its constituent polypeptide chains ($A\alpha$, $B\beta$ and γ), 60 μ l of bovine
243 fibrinogen stock solution (1 mg/ml) was mixed with 350 μ l of gel loading buffer (100 mM Tris-
244 Cl [pH 6.8] 4% SDS, 0.2% bromophenol blue, 20 % glycerol, 200 mM dithiothreitol, heated at
245 95°C for 5 minutes and separated in Tris-glycine polyacrylamide gels by SDS-PAGE (4-20 %
246 gradient gel) at a constant voltage of 180 V for 50 minutes. The fibrinogen chains were
247 electroblotted onto a nitrocellulose membrane (100 V, 240 mA, 120 minutes) and the
248 membrane was blocked with 5% (w/v) skimmed milk. Membranes were subsequently
249 incubated with 30 μ g/ml recombinant protein. Any bound protein was detected by incubation
250 of the membrane with mouse anti-polyhistidine antibody (Sigma-Aldrich, Dorset, UK), diluted
251 1:2000 followed by goat anti-mouse antibody (Sigma-Aldrich, Dorset, UK) and development
252 in 3,3'-diaminobenzidine membrane substrate (Sigma-Aldrich, Dorset, UK).

253 **Immunogenicity trial in calves.**

254 *Calves.*

255 The immunogenicity of the recombinant proteins was evaluated in two Holstein-Friesian
256 calves. A control group of two additional calves was used to verify that any serological
257 response did not result from environmental exposure to BDD-associated treponemes or to
258 ubiquitous antigens.

259 The four calves were reared and maintained according to routine agricultural practice at the
260 University's Farm with housing conditions having increased biosecurity to reduce the risk of
261 exposure to the BDD-associated *Treponema* spp.. Calves were bedded on straw and

262 quarantined for 4 weeks before vaccine administration. Calves were bled immediately prior
263 to vaccine administration to ascertain pre-immunisation antibody status.

264 *Formulation of the vaccine.*

265 The multivalent vaccine was formulated to deliver the four recombinant proteins
266 simultaneously and comprised of 100 µg of each recombinant protein and 40 µl aluminium
267 hydroxide adjuvant (Rehydragel®, Chemtrade Logistics, Toronto, Ontario), adjusted to a final
268 volume of 2 ml using PBS. All vaccines were administered subcutaneously to the left flank.
269 Calves received an initial 2 ml dose of the vaccine followed by a 2 ml booster dose two weeks
270 later. Concurrently, Control animals (n=2) received a 2 ml dose of the vehicle only. Blood
271 samples, obtained by jugular venepuncture, were collected at two-week intervals for four
272 weeks beginning with a pre-immunisation draw at day zero. Serum was retained for
273 serological studies.

274 *Detection of serum IgG antibodies by ELISA.*

275 Vaccinee IgG1 and IgG2 antibody seroreactivity to the recombinant proteins was determined
276 as described previously in this manuscript. All data was processed and analysed using
277 GraphPad Prism 5 (GraphPad, San Diego, CA). ELISA reactivity was confirmed by Western blot
278 analysis using previously described methods (23).

279 **RESULTS.**

280 *In silico detection of putative treponemal OMPs.*

281 SignalP 4.1 analysis identified 182 *T. medium* T19 CDS features predicted to contain an N-
282 terminal peptidase I cleavage site. These features were further analysed by three β-barrel
283 prediction programs: BOMP, PRED-TMBB and TMBETA-NET. CDS features predicted to

284 encode β -barrel proteins by at least one these programs were selected for cross-phylogroup
285 homology detection. In total, fifteen CDS features identified in the *T. medium* T19 genome
286 matched the following selection criteria precisely: i) the presence of a signal peptidase I
287 cleavage site, ii) a predicted β -barrel topology and iii) cross-phylogroup homology (Table 2).
288 Four CDS features, two from the *T. medium* genome and two from the *T. pedis* genome
289 (including one homologous pair: C5N99_10335 and DYQ05_13425; amino acid sequence
290 identity 31.87%) were subsequently selected to evaluate their ability to bind to selected ECM
291 components and to induce an IgG antibody response in calves.

292 *Prediction of 3-dimensional (3D) tertiary structure.*

293 To generate predicted 3D structural models, each protein sequence was submitted to the I-
294 TASSER server. The highest-ranking model for each protein is shown in Fig. 1. The four
295 putative OMPs were each predicted to contain a typical β -barrel domain, consistent with
296 localisation to the outer membrane of gram-negative bacteria.

297 Typical β -barrel structures were predicted for C5N99_10335, DYQ05_13425 and
298 DYQ05_06810, whereas C5N99_02965 was predicted to adopt a β -solenoid fold.

299 *Heat-modifiability assay.*

300 Three of the proteins expressed a heat-modifiable electrophoretic mobility, consistent with
301 the stability of a protein comprising predominantly of a β -structure (66). Fig. 2 shows the
302 change in electrophoretic mobility observed under unheated versus heated conditions for
303 C5N99_10335, C5N99_02965 and DYQ05_06810.

304 Heat modification of C5N99_02965 (Fig. 2A) led to a change in electrophoretic mobility and a
305 change in the apparent MW, from \sim 30 to \sim 36 kDa. Similar changes in mobility were observed

306 for C5N99_10335 (Fig 2B; ~22 to ~24 kDa) and DYQ05_06810 (Fig 2C; ~21 to 23 kDa). Heat
307 modifiability was not identified for DYQ05_13425 (data not shown).

308 *CD spectroscopic analysis of the treponemal recombinant OMP secondary structure.*

309 Far UV CD spectroscopy was employed to provide further evidence of the secondary structure
310 fold of these proteins (Fig. 3). Consistent with a predicted β -barrel tertiary structure state,
311 analysis of the four putative OMPs yielded spectral signatures typical of a predominantly β -
312 sheet secondary structure, with spectral minima occurring at approximately 218 nm for
313 C5N99_10335, C5N99_02965, DYQ05_06810 and DYQ05_13425 as well as the positive
314 control protein, OmpL1.

315 *Serological response to putative OMPs during natural BDD infection.*

316

317 As demonstrated in Fig 4, IgG2 seroreactivity to DYQ05_06810 was detected in BDD-infected
318 Holstein Friesian cows (n=12; 75%) relative to the healthy control animals, with no apparent
319 IgG2 response observed against the remaining three putative OMPs. No IgG1 response was
320 identified against any of the putative OMPs under investigation. A statistically significant
321 decrease in the IgG1 ELISA ODs was observed in the sera of BDD-exposed animals, relative to
322 controls, in the *T. medium*/T19 putative OMP analyses ($P<0.05$).

323 *Binding of the treponemal OMPs to ECM components.*

324 Statistically significant ($P<0.05$) adherence to fibrinogen, elastin and heparan sulphate was
325 observed for both C5N99_10335 and C5N99_02965, with C5N99_10335 additionally adhering
326 to fibronectin (Fig. 5).

327 The *T. pedis* homologue of C5N99_10335, namely DYQ05_13425, exhibited a similar binding
328 profile to C5N99_10335, but was found to additionally bind to chondroitin. DYQ05_06810
329 bound to fibronectin, fibrinogen, elastin, chondroitin and heparan sulphate.

330 Next, given the ubiquitous fibrinogen binding amongst these putative treponemal OMPs (P
331 <0.01), we sought to further characterise this interaction across a concentration range. The
332 results of these analyses are shown in Fig. 6.

333 The binding interactions between fibrinogen and C5N99_10335, C5N99_02965,
334 DYQ05_06810 and DYQ05_13425 were observed to be concentration-dependent. Binding
335 saturation levels were achieved with recombinant protein concentrations of ~1 μ M, ~1.5 μ M,
336 and ~2.0 μ M for C5N99_02965, DYQ05_13425 and DYQ05_06810, respectively. Conversely,
337 C5N99_10335, although showing a tendency towards reaching saturation, failed to do so up
338 to a concentration of 2 μ M. Further examination of this interaction was precluded by
339 insufficient protein yield. K_D values were estimated by non-linear regression analysis of the
340 binding curves. Table 4 summarises the K_D values calculated from these experiments. The
341 positive control protein, OmpL1, was similarly observed to adhere to bovine fibrinogen in a
342 dose-dependent and saturable manner as previously reported (47) (data not shown).

343 *Far western blotting.*

344 Far Western blotting identified interactions between the putative OMPs and individual chains
345 of the fibrinogen molecule. The results of this analysis are shown in Fig. 7.

346 The results of the far western analysis revealed that DYQ05_13425 and DYQ05_06810
347 interacted with all three chains of the fibrinogen molecule, similarly to OmpL1. Conversely,

348 C5N99_10335 and C5N99_02965 were observed to interact with the β and γ chains of
349 fibrinogen only.

350 *Immunogenicity.*

351 The immunogenic properties of these four fibrinogen-binding proteins were investigated
352 following inoculation into two naïve bull calves as part of a multivalent antigen cocktail. ELISA
353 analysis of pre-vaccination sera yielded broadly comparable ELISA ODs between calves.

354 This pilot immunogenicity trial demonstrated that this subcutaneous prime-boost vaccination
355 protocol, involving an aluminium hydroxide-adjuvanted 100 μg dose of each treponemal
356 recombinant OMP, is capable of eliciting IgG antibodies in BDD-naïve bull calves (Fig. 8). All
357 animals vaccinated with the recombinant protein cocktail seroconverted rapidly, permitting
358 treponemal OMP-specific IgG antibody detection by day 14. A second booster vaccination on
359 day 14 enhanced the IgG response further and specific antibody titres peaked at day 28. No
360 seroconversion was detected in the control animals up to day 56 (the last day of the trial; data
361 not shown). The fold-change, calculated as the mean OD change on day 28 from pre-
362 immunisation baseline (Table 5) was used to account for varying baseline ELISA ODs.

363 Whilst all recombinant proteins were shown to be immunogenic under the conditions of this
364 trial, C5N99_10335 was found to be the weakest driver of both an IgG1 and IgG2 antibody
365 response, with ELISA OD fold changes calculated to be 2.37 and 1.66 from baseline,
366 respectively. DYQ05_13425, conversely, was found to be the most potent immunogen, with
367 ELISA OD fold-changes from baseline calculated to be 7.44 and 9.10, for IgG1 and IgG2,
368 respectively. The specificity of the anti-sera was confirmed using Western Blotting and
369 revealed the presence of treponemal putative OMP-specific IgG1 and IgG2 serum antibodies
370 in immunised animals only (data not shown). Serological analysis on day 42 of the trial

371 revealed a slight waning of the IgG antibody response in all cases. The trial vaccine was well
372 tolerated in vaccinated calves.

373 **DISCUSSION.**

374 Using a bioinformatics-based approach, the present study sought to identify and characterise
375 novel BDD-associated treponemal OMPs, bearing in mind the potential value of these
376 molecules as BDD vaccine candidates. Post-purification analysis of the four refolded proteins
377 by CD spectroscopy yielded spectra indicative of a predominantly β -strand secondary
378 structure with three of the proteins (C5N99_10335, C5N99_02965 and DYQ05_06810)
379 additionally demonstrated to be heat-modifiable. These findings are consistent with the
380 characteristics of proteins with a β -barrel tertiary structure. Conversely, DYQ05_13425 was
381 found to not be heat-modifiable. Owing to a highly resistant tertiary-structure, some bacterial
382 OMPs exhibit an unusual stability to heat in the presence of SDS and an extended heating
383 period may be required to convert such proteins to their denatured form, as reported for
384 Protein F from *P. aeruginosa* (67) and OmpL1 from *L. interrogans* (66).

385 Examination by ELISA of IgG seroreactivity in animals naturally infected with BDD revealed
386 that only one protein (DYQ05_06810) was capable of discriminating clearly between the sera
387 of animals with recent or active BDD infection and cattle presumed not to have been exposed
388 to the BDD treponemes. In identifying a disease-specific IgG2 antibody response to
389 DYQ05_06810, these findings are in concordance with the findings of a number of previous
390 studies that demonstrated a strong anti-treponemal IgG2 bias in the antibody response of
391 animals naturally infected with BDD (68–70). These data suggest that whilst DYQ05_06810 is
392 accessible to the immune system during treponemal infection (and thus capable of eliciting
393 IgG2 antibodies), the remaining three putative treponemal OMPs may be expressed as

394 subdominant antigens or their expression may be immunosubversive in nature.
395 Unexpectedly, a reduction in OD was observed when comparing the IgG1 response to the two
396 *T. medium*/T19 putative OMPs in cows exposed to BDD relative to healthy controls. The
397 reasons for this are unclear, although treponemes exhibit a number of immunosuppressive
398 functions capable of interfering with both innate (71) and adaptive immune activity (72), the
399 utilisation of which is likely to contribute to infection chronicity. In this case, it is speculated
400 that whereas previous colonisation with bacteria expressing orthologues of C5N99_10335
401 and C5N99_02965 leads to the production of cross-reactivity antibodies (which are
402 detectable in control animals), subsequent infection with *T. medium* leads to a reduction in
403 the serotitre of these antibodies via immunosuppressive mechanisms. Crucially, both proteins
404 have been detected in the transcriptome of BDD lesions (73) and studies are required to
405 investigate their capacity to modulate host immunity.

406 Presently, no commercially available serological assay to detect BDD treponemes is available
407 for field diagnostics and immunoassay-based serological assessment of BDD in research
408 settings is currently dependent on the use of whole cell lysates. The *T. phagedenis* putative
409 proline-rich repeat lipoprotein, PrrA, was previously identified as an immunogenic protein of
410 *T. phagedenis*-like strain V1 (isolated from a BDD lesion) and as an antigenic target capable of
411 discriminating between animals acutely infected with BDD (n=8) and BDD naïve animals (n=7)
412 (74). An ELISA, capable of detecting bovine anti-PrrA antibodies in serum and milk, has been
413 available to the research community for some time, although there are currently no reports
414 detailing post-marketing experience. In addition, the PrrA gene and its product have been
415 absent from several *T. phagedenis*-like BDD lesion isolates (74, 75), potentially limiting the
416 value of this ELISA as a means of determining herd infection status. It is therefore proposed
417 that the IgG2 antibody response to DYQ05_06810 be further evaluated as a potential

418 antigenic marker of seroconversion in BDD-infected animals. The diagnosis of BDD currently
419 remains restricted to clinical examination of the lifted foot by means of individual restraint
420 (76) and specificity and sensitivity are limited by subjectivity and observer-bias (77). A
421 quantitative diagnostic ELISA is less labour-intensive, less time consuming, and is a more
422 reproducible indicator of biological infection (78). Since these recombinant molecules can be
423 readily synthesised in *E. coli* expression systems, the difficulties in cultivating BDD-associated
424 *Treponema* spp. for whole-cell antigen preparations are bypassed.

425 An initial ECM binding screen demonstrated that the putative treponemal β -barrel OMPs
426 identified in this study exhibited ECM-adhesive properties, supporting their role in bacterial
427 cytoadherence to host tissues. Interestingly, these proteins exhibited multispecific ECM
428 binding profiles. One of the most striking properties of the putative treponemal OMPs was an
429 ability to adhere to immobilised bovine fibrinogen. Because of the highly significant nature of
430 this interaction, these fibrinogen binding activities were investigated further and found to be
431 concentration-dependent and saturable, suggesting the existence of fibrinogen-specific
432 binding sites. The estimated dissociation constants (K_D) (0.34 and 0.72 for C5N99_02965 and
433 DYQ05_13425, respectively) broadly align with those calculated for other spirochaetal
434 fibrinogen binding proteins, including the leptospiral proteins OmpL1 (0.223 μ M) (47),
435 OmpL37 (0.244 μ M) (79) and Lsa33 (0.12 μ M) (80), supporting the relevance of these
436 interactions *in vivo*. DYQ05_06810 exhibited a higher estimated K_D of 1.0 μ M, and is of a
437 similar magnitude to other biologically-relevant ECM binding interactions, including those
438 reported for OmpL1 interactions with laminin ($K_D = 2.10 \mu$ M) and fibronectin ($K_D = 1.24 \mu$ M)
439 (46).

440 Bovine fibrinogen is a 340-kDa dimeric glycoprotein comprising of three pairs of non-identical
441 A α (~67 kDa), B β (~55 kDa) and γ (~48 kDa) peptide chains. Fibrinogen is a major clotting
442 factor and performs an essential role in preventing haemorrhage and facilitating vascular
443 repair. At sites of tissue damage, fibrinogen is found embedded with the extracellular matrix
444 (81). It has previously been demonstrated that successful and consistent experimental
445 transmission of BDD requires abrasion of the skin (82). Abrasive trauma would be expected
446 to lead to enhanced fibrinogen deposition and it is therefore hypothesized that ECM-
447 associated fibrinogen represents an adherence target during the initial stage of host
448 colonisation. In support of this hypothesis, it has been demonstrated previously that two *T.*
449 *medium*-like treponemal strains, UB1467 and UB1090, isolated from a bovine and an ovine
450 DD lesion, and a *T. pedis*-like strain, UB1466, isolated from an ovine DD lesion, were all
451 capable of adhering to immobilised fibrinogen (83). Thus, adhesin-mediated treponemal
452 adherence to the host via such interactions may be central to the treponemal infection, in
453 which abrasive trauma may be necessary point of entry.

454 Soluble host proteins, including plasma fibrinogen, may act as a diffuse peptide nutrient
455 source within inflamed tissues. However, fibrinogen additionally plays a direct role in
456 antimicrobial host defence. Firstly, thrombin-catalysed conversion to insoluble fibrin clots
457 leads to the formation of a structural protective barrier capable of containing bacteria and
458 preventing dissemination (84). Secondly, this conversion to thrombin leads to the release of
459 potent chemotactic elements, including fibrinopeptide B, which drives an influx of phagocytes
460 (85). Amongst the treponemal OMPs, Chymotrypsin-Like Protease (CTLP) from *T. denticola*
461 and Tp0751 (Pallysilin) from *T. pallidum* subs. *pallidum*, are both capable of adhering to
462 fibrinogen whilst additionally exhibiting fibrinogenolytic protease activity, with important
463 deleterious consequences for platelet homeostasis and clot formation (29, 86). BDD lesions

464 tend to bleed readily upon palpation (87), and a disturbance in the coagulation pathway
465 arising from treponemal fibrinogen targeting is suspected. The interactions observed
466 between the recombinant proteins and specific chains of the fibrinogen molecule identified
467 in the present study may support this hypothesis, since the four recombinant proteins
468 exhibited the capacity to adhere to all three fibrinogen chains or the beta and gamma chains
469 only. Crucially, platelet aggregation is dependent on the binding of platelet membrane
470 glycoprotein IIa/IIIb to the fibrinogen A α and γ chain (88) and previous studies have identified
471 selective fibrinogen chain targeting by pathogenic OMPs. For instance, targeting of the γ chain
472 of fibrinogen has been previously reported by *S. aureus* clumping factor A (89), leading to
473 disturbances in platelet aggregation, fibrin clot formation and platelet-mediated clot
474 retraction (90).

475 The mechanisms that underpin the observed interactions with fibrinogen are unknown and
476 require further investigation. Further studies, using gene mutagenesis and critical binding
477 domain mapping, are required to fully understand the molecular basis for these interactions.
478 It is noteworthy that these proteins appear to adhere to a number of other ECM components,
479 demonstrating the apparent multi-specificity of these putative treponemal adhesins.
480 Although we have not yet explored these interactions further, this suggests that these
481 molecules may be functionally similar to a number of other spirochaetal OMPs capable of
482 adhering to multiple ligands, including Tp0751 (29) and OmpL1 (46). This presumably
483 represents an evolutionary adaptation that minimises bacterial surface immunogenicity
484 whilst preserving adhesive function.

485 Given the apparent importance of these putative OMPs to fibrinogen (and other ligands), and
486 their potential roles in host colonisation and pathogenicity, we sought to assess their

487 immunogenic properties. Previous studies have shown that anti-adhesin antibodies, elicited
488 by vaccination, have the potential to protect the host (91, 92) and it is hypothesised that
489 blockade of these putative OMPs would impede host colonisation and/or virulence. Previous
490 attempts at designing a BDD vaccine have been limited to the use of treponemal whole-cell
491 lysate 'bacterin' formulations of a single phylotype, and field trials have been disappointing
492 (93). The subcutaneous vaccine formulation evaluated in the present study was designed
493 specifically to induce an IgG response against putative treponemal fibrinogen-binding OMPs,
494 which may be critical to host colonisation, yet exist as subdominant antigens with little or no
495 immunogenic capacity in natural infection.

496 Since recombinant protein antigens tend to be relatively weak antigens (94), aluminium
497 hydroxide was employed as an adjuvant. Both an IgG1 and an IgG2 response to the putative
498 OMP antigens was generated for the four proteins tested. Moreover, fold-change in the ELISA
499 ODs generated for IgG1, relative to IgG2, was generally greater. Aluminium compounds are
500 considered to be principally promoters of Th2 polarisation, at least in humans and mice (95,
501 96), and may explain the IgG1 subclass bias observed in this study. A mixed IgG1/IgG2 or IgG1-
502 polarised host response may prove to be an important correlate of protection against an
503 infection that is usually considered to induce a non-protective, yet robust, IgG2 response (68–
504 70). However, because a later study identified IgG1 as the predominant IgG subclass in cattle
505 both naturally exposed to BDD and experimentally infected with BDD-associated treponemes
506 (97), there exists considerable uncertainty of the nature of the bovine immune response in
507 BDD and subsequently, its potential for manipulation.

508 The four proteins evaluated were found to be immunogenic in both calves in the treatment
509 group; only C5N99_10335 was found to be non-immunogenic in one of the two calves

510 immunised with this antigen, highlighting the heterogeneity of the immune response
511 between vaccinees. Whether this apparent variation in immunogenicity has arisen from
512 intrinsic differences in the molecular structures of these recombinant proteins, host-specific
513 variations in immune response or potential contamination with endogenous endotoxin, has
514 not been established. Moreover, whilst the immunogenic potential of these putative OMPs
515 has been demonstrated here, neither the duration of the IgG response or its magnitude (in
516 terms of absolute antibody titre) was established. Since the immunised calves were not
517 assessed for post-vaccination susceptibility to BDD, it is unknown whether high titres of the
518 IgG antibodies generated during this study correlate with protection against disease and
519 future studies are warranted. However, these data indicate successful B cell priming after the
520 initial vaccination with a boost effect following the second vaccination, both of which are
521 important characteristics of a vaccine component.

522 Given the difficulties associated with the isolation, cultivation and purification of the BDD
523 treponemes, the development of a vaccine against BDD has previously been substantially
524 hindered. This *in silico* approach to novel OMP identification overcomes the challenges of
525 traditional vaccine design methods. To this end, we report on the identification and
526 characterisation of four putative adhesins, selected from the sequenced genomes of *T.*
527 *medium* and *T. pedis* phylogroups, two of the principle treponeme taxa associated with BDD.
528 Further studies are justified to establish their value as BDD vaccine candidates.

529 **Acknowledgements**

530 This work was supported by a BBSRC New Investigator Award (BB/K009443/1) awarded to
531 Nicholas Evans and an industrial research grant from Zoetis Inc. awarded to Stuart Carter and
532 Nicholas Evans.

533 **References**

- 534 1. Blowey RW, Sharp MW. 1988. Digital dermatitis in dairy cattle. *Vet Rec* 122:505–8.
- 535 2. Read DH, Walker RL. 1998. Papillomatous digital dermatitis (footwarts) in California
536 dairy cattle: clinical and gross pathologic findings. *J Vet Diagnostic Investig* 10:67–76.
- 537 3. Zinicola M, Lima F, Lima S, Machado V, Gomez M, Döpfer D, Guard C, Bicalho R. 2015.
538 Altered Microbiomes in Bovine Digital Dermatitis Lesions, and the Gut as a Pathogen
539 Reservoir. *PLoS One* 10:e0120504.
- 540 4. Barker ZE, Leach KA, Whay HR, Bell NJ, Main DCJ. 2010. Assessment of lameness
541 prevalence and associated risk factors in dairy herds in England and Wales. *J Dairy Sci*
542 93:932–941.
- 543 5. Sullivan LE, Carter SD, Blowey R, Duncan JS, Grove-White D, Evans NJ. 2013. Digital
544 dermatitis in beef cattle. *Vet Rec* 173:582.1-582.
- 545 6. Sullivan LE, Evans NJ, Blowey RW, Grove-White DH, Clegg SR, Duncan JS, Carter SD.
546 2015. A molecular epidemiology of treponemes in beef cattle digital dermatitis
547 lesions and comparative analyses with sheep contagious ovine digital dermatitis and
548 dairy cattle digital dermatitis lesions. *Vet Microbiol* 178:77–87.
- 549 7. Davies IH, Naylor RD, Martin PK. 1999. Severe ovine foot disease. *Vet Rec* 145:646.
- 550 8. Harwood DG, Cattell JH, Lewis CJ, Naylor R. 1997. Virulent foot rot in sheep. *Vet Rec*
551 140:687.
- 552 9. Walker RL, Read DH, Loretz KJ, Nordhausen RW. 1995. Spirochetes isolated from dairy
553 cattle with papillomatous digital dermatitis and interdigital dermatitis. *Vet Microbiol*

- 554 47:343–55.
- 555 10. Krull AC, Shearer JK, Gorden PJ, Cooper VL, Phillips GJ, Plummer PJ. 2014. Deep
556 Sequencing Analysis Reveals Temporal Microbiota Changes Associated with
557 Development of Bovine Digital Dermatitis. *Infect Immun* 82:3359–3373.
- 558 11. Nielsen MW, Strube ML, Isbrand A, Al-Medراسي WD, Boye M, Jensen TK, Klitgaard K.
559 2016. Potential bacterial core species associated with digital dermatitis in cattle herds
560 identified by molecular profiling of interdigital skin samples. *Vet Microbiol* 186:139–
561 149.
- 562 12. Evans NJ, Brown JM, Demirkan I, Singh P, Getty B, Timofte D, Vink WD, Murray RD,
563 Blowey RW, Birtles RJ, Hart CA, Carter SD. 2009. Association of Unique, Isolated
564 *Treponemes* with Bovine Digital Dermatitis Lesions. *J Clin Microbiol* 47:689–696.
- 565 13. Evans NJ, Brown JM, Demirkan I, Murray RD, Birtles RJ, Hart CA, Carter SD. 2009.
566 *Treponema pedis* sp. nov., a spirochaete isolated from bovine digital dermatitis
567 lesions. *Int J Syst Evol Microbiol* 59:987–991.
- 568 14. Evans NJ, Brown JM, Demirkan I, Murray RD, Vink WD, Blowey RW, Hart CA, Carter
569 SD. 2008. Three unique groups of spirochetes isolated from digital dermatitis lesions
570 in UK cattle. *Vet Microbiol* 130:141–150.
- 571 15. Rasmussen M, Capion N, Klitgaard K, Rogdo T, Fjeldaas T, Boye M, Jensen TK. 2012.
572 Bovine digital dermatitis: Possible pathogenic consortium consisting of *Dichelobacter*
573 *nodosus* and multiple *Treponema* species. *Vet Microbiol* 160:151–161.
- 574 16. Moter A, Leist G, Rudolph R, Schrank K, Choi B-K, Wagner M, Gobel UB. 1998.
575 Fluorescence in situ hybridization shows spatial distribution of as yet uncultured

- 576 treponemes in biopsies from digital dermatitis lesions. *Microbiology* 144:2459–2467.
- 577 17. Choi B-K, Natterman H, Grund S, Haider W, Gobel UB. 1997. Spirochetes from Digital
578 Dermatitis Lesions in Cattle Are Closely Related to Treponemes Associated with
579 Human Periodontitis. *Int J Syst Bacteriol* 47:175–181.
- 580 18. Evans NJ, Timofte D, Isherwood DR, Brown JM, Williams JM, Sherlock K, Lehane MJ,
581 Murray RD, Birtles RJ, Anthony Hart C, Carter SD. 2012. Host and environmental
582 reservoirs of infection for bovine digital dermatitis treponemes. *Vet Microbiol*
583 156:102–109.
- 584 19. Gomez A, Anklam KS, Cook NB, Rieman J, Dunbar KA, Cooley KE, Socha MT, Döpfer D.
585 2014. Immune response against *Treponema* spp. and ELISA detection of digital
586 dermatitis. *J Dairy Sci* 97:4864–4875.
- 587 20. Elliott MK, Alt DP. 2009. Bovine immune response to papillomatous digital dermatitis
588 (PDD)-associated spirochetes is skewed in isolate reactivity and subclass elicitation.
589 *Vet Immunol Immunopathol* 130:256–261.
- 590 21. Trott DJ, Moeller MR, Zuerner RL, Goff JP, Waters WR, Alt DP, Walker RL,
591 Wannemuehler MJ. 2003. Characterization of *Treponema phagedenis*-like spirochetes
592 isolated from papillomatous digital dermatitis lesions in dairy cattle. *J Clin Microbiol*
593 41:2522–9.
- 594 22. Moe KK, Yano T, Misumi K, Kubota C, Yamazaki W, Muguruma M, Misawa N. 2010.
595 Analysis of the IgG immune response to *Treponema phagedenis*-like spirochetes in
596 individual dairy cattle with papillomatous digital dermatitis. *Clin Vaccine Immunol*
597 17:376–383.

- 598 23. Demirkan I, Walker RL, Murray RD, Blowey RW, Carter SD. 1999. Serological evidence
599 of spirochaetal infections associated with digital dermatitis in dairy cattle. *Vet J* 69–
600 77.
- 601 24. Smirbert RM. 1984. Genus III Treponema, p. 49–57. *In* Krieg, NR, Holt, JG (eds.),
602 Bergey's manual of systematic bacteriology. Williams & Wilkins, Baltimore, MD.
- 603 25. Dawson JR, Ellen RP. 1990. Tip-Oriented Adherence of *Treponema denticola* to
604 Fibronectin. *Infect Immun* 58:3924–3928.
- 605 26. Fitzgerald TJ, Repesh LA, Blanco DR, Miller JN. 1984. Attachment of *Treponema*
606 *pallidum* to fibronectin, laminin, collagen IV, and collagen I, and blockage of
607 attachment by immune rabbit IgG. *Br J Vener Dis* 60:357–63.
- 608 27. Brinkman MB, McGill MA, Petterson J, Rogers A, Matejková P, Smajs D, Weinstock
609 GM, Norris SJ, Palzkill T. 2008. A novel *Treponema pallidum* antigen, TP0136, is an
610 outer membrane protein that binds human fibronectin. *Infect Immun* 76:1848–57.
- 611 28. Parker ML, Houston S, Pětrošová H, Lithgow K V, Hof R, Wetherell C, Kao W-C, Lin Y-
612 P, Moriarty TJ, Ebady R, Cameron CE, Boulanger MJ. 2016. The Structure of
613 *Treponema pallidum* Tp0751 (Pallilysin) Reveals a Non-canonical Lipocalin Fold That
614 Mediates Adhesion to Extracellular Matrix Components and Interactions with Host
615 Cells. *PLOS Pathog* 12:e1005919.
- 616 29. Houston S, Hof R, Francescutti T, Hawkes A, Boulanger MJ, Cameron CE. 2011.
617 Bifunctional role of the *Treponema pallidum* extracellular matrix binding adhesin
618 Tp0751. *Infect Immun* 79:1386–1398.
- 619 30. Cameron CE, Brouwer NL, Tisch LM, Kuroiwa JMY. 2005. Defining the Interaction of

- 620 the *Treponema pallidum* Adhesin Tp0751 with Laminin. *Infect Immun* 73:7485–7494.
- 621 31. Cameron CE. 2003. Identification of a *Treponema pallidum* laminin-binding protein.
622 *Infect Immun* 71:2525–33.
- 623 32. Haapasalo M, Müller KH, Uitto VJ, Leung WK, McBride BC. 1992. Characterization,
624 cloning, and binding properties of the major 53-kilodalton *Treponema denticola*
625 surface antigen. *Infect Immun* 60:2058–65.
- 626 33. Fenno JC, Müller KH, McBride BC. 1996. Sequence analysis, expression, and binding
627 activity of recombinant major outer sheath protein (Msp) of *Treponema denticola*. *J*
628 *Bacteriol* 178:2489–97.
- 629 34. Anand A, Luthra A, Edmond ME, Ledoyt M, Caimano MJ, Radolf JD. 2013. The major
630 outer sheath protein (Msp) of *Treponema denticola* has a bipartite domain
631 architecture and exists as periplasmic and outer membrane-spanning conformers. *J*
632 *Bacteriol* 195:2060–71.
- 633 35. Gaibani P, Pellegrino MT, Rossini G, Alvisi G, Miragliotta L, Prati C, Sambri V. 2010.
634 The central region of the msp gene of *Treponema denticola* has sequence
635 heterogeneity among clinical samples, obtained from patients with periodontitis.
636 *BMC Infect Dis* 10:345.
- 637 36. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B. 2000.
638 Artemis: sequence visualization and annotation. *Bioinformatics* 16:944–5.
- 639 37. Petersen TN, Brunak S, von Heijne G, Nielsen H. 2011. SignalP 4.0: discriminating
640 signal peptides from transmembrane regions. *Nat Methods* 8:785–786.
- 641 38. Berven FS, Flikka K, Jensen HB, Eidhammer I. 2004. BOMP: a program to predict

- 642 integral β -barrel outer membrane proteins encoded within genomes of Gram-negative
643 bacteria. *Nucleic Acids Res* 32:W394–W399.
- 644 39. Gromiha MM, Ahmad S, Suwa M. 2005. TMBETA-NET: discrimination and prediction
645 of membrane spanning β -strands in outer membrane proteins. *Nucleic Acids Res*
646 33:W164–W167.
- 647 40. Bagos PG, Liakopoulos TD, Spyropoulos IC, Hamodrakas SJ. 2004. PRED-TMBB: a web
648 server for predicting the topology of β -barrel outer membrane proteins. *Nucleic Acids*
649 *Res* 32:W400–W404.
- 650 41. Enright AJ, Van Dongen S, Ouzounis CA. 2002. An efficient algorithm for large-scale
651 detection of protein families. *Nucleic Acids Res* 30:1575–84.
- 652 42. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment
653 search tool. *J Mol Biol* 215:403–410.
- 654 43. Sachdeva G, Kumar K, Jain P, Ramachandran S. 2005. SPAAN: a software program for
655 prediction of adhesins and adhesin-like proteins using neural networks.
656 *Bioinformatics* 21:483–491.
- 657 44. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. *BMC*
658 *Bioinformatics* 9:40.
- 659 45. Chua PKB, Corkill JE, Hooi PS, Cheng SC, Winstanley C, Hart CA. 2005. Isolation of
660 *Waddlia malaysiensis*, a novel intracellular bacterium, from fruit bat (*Eonycteris*
661 *spelaea*). *Emerg Infect Dis* 11:271–7.
- 662 46. Fernandes LG V., Vieira ML, Kirchgatter K, Alves IJ, Morais ZM de, Vasconcellos SA,
663 Romero EC, Nascimento ALTO. 2012. OmpL1 Is an Extracellular Matrix- and

- 664 Plasminogen-Interacting Protein of *Leptospira* spp. *Infect Immun* 80:3679.
- 665 47. Robbins GT, Hahn BL, Evangelista K V., Padmore L, Aranda PS, Coburn J. 2015.
666 Evaluation of Cell Binding Activities of *Leptospira* ECM Adhesins. *PLoS Negl Trop Dis*
667 9:e0003712.
- 668 48. Haake DA, Champion CI, Martinich C, Shang ES, Blanco DR, Miller JN, Lovett MA.
669 1993. Molecular cloning and sequence analysis of the gene encoding OmpL1, a
670 transmembrane outer membrane protein of pathogenic *Leptospira* spp. *J Bacteriol*
671 175:4225–34.
- 672 49. Prince SM, Feron C, Janssens D, Lobet Y, Achtman M, Kusecek B, Bullough PA, Derrick
673 JP. 2001. Expression, refolding and crystallization of the OpcA invasin from *Neisseria*
674 meningitidis. *Acta Crystallogr D Biol Crystallogr* 57:1164–6.
- 675 50. Porath J, Carlsson J, Olsson I, Belfrage G. 1975. Metal chelate affinity
676 chromatography, a new approach to protein fractionation. *Nature* 258:598–9.
- 677 51. Schweizer M, Hindennach I, Garten W, Henning U. 1978. Major proteins of the
678 *Escherichia coli* outer cell envelope membrane. Interaction of protein II with
679 lipopolysaccharide. *Eur J Biochem* 82:211–7.
- 680 52. Micsonai A, Wien F, Kernya L, Lee Y-H, Goto Y, Réfrégiers M, Kardos J. 2015. Accurate
681 secondary structure prediction and fold recognition for circular dichroism
682 spectroscopy. *Proc Natl Acad Sci* 112:E3095–E3103.
- 683 53. Ji B, Collins MT. 1994. Seroepidemiologic survey of *Borrelia burgdorferi* exposure of
684 dairy cattle in Wisconsin. *Am J Vet Res* 55:1228–31.
- 685 54. Cameron CE. 2003. Identification of a *Treponema pallidum* laminin-binding protein.

- 686 Infect Immun 71:2525–33.
- 687 55. Pathirana RD, O’Brien-Simpson NM, Veith PD, Riley PF, Reynolds EC. 2006.
688 Characterization of proteinase-adhesin complexes of *Porphyromonas gingivalis*.
689 Microbiology 152:2381–2394.
- 690 56. Lin Y-P, Lee D-W, McDonough SP, Nicholson LK, Sharma Y, Chang Y-F. 2009. Repeated
691 Domains of *Leptospira* Immunoglobulin-like Proteins Interact with Elastin and
692 Tropoelastin. J Biol Chem 284:19380–19391.
- 693 57. Wu Y, Li Q, Chen X-Z. 2007. Detecting protein–protein interactions by far western
694 blotting. Nat Protoc 2:3278–3284.
- 695 58. Li H, Zhang W, Dong C. 2018. Crystal structure of the outer membrane protein OmpU
696 from *Vibrio cholerae* at 2.2 Å resolution. Acta Crystallogr Sect D, Struct Biol 74:21–29.
- 697 59. Zhao H, Sequeira RD, Galeva NA, Tang L. 2011. The host outer membrane proteins
698 OmpA and OmpC are associated with the *Shigella* phage Sf6 virion. Virology 409:319–
699 27.
- 700 60. Torres AG, Kaper JB. 2003. Multiple Elements Controlling Adherence of
701 Enterohemorrhagic *Escherichia coli* O157:H7 to HeLa Cells. Infect Immun 71:4985–
702 4995.
- 703 61. Zahn M, D’Agostino T, Eren E, Baslé A, Ceccarelli M, van den Berg B. 2015. Small-
704 Molecule Transport by CarO, an Abundant Eight-Stranded β-Barrel Outer Membrane
705 Protein from *Acinetobacter baumannii*. J Mol Biol 427:2329–39.
- 706 62. Vandeputte-Rutten L, Kramer RA, Kroon J, Dekker N, Egmond MR, Gros P. 2001.
707 Crystal structure of the outer membrane protease OmpT from *Escherichia coli*

- 708 suggests a novel catalytic site. *EMBO J* 20:5033–9.
- 709 63. Sequeira S, Kavanaugh D, MacKenzie DA, Šuligoj T, Walpole S, Leclaire C, Gunning AP,
710 Latousakis D, Willats WGT, Angulo J, Dong C, Juge N. 2018. Structural basis for the
711 role of serine-rich repeat proteins from *Lactobacillus reuteri* in gut microbe-host
712 interactions. *Proc Natl Acad Sci U S A* 115:E2706–E2715.
- 713 64. Touw DS, Patel DR, van den Berg B. 2010. The crystal structure of OprG from
714 *Pseudomonas aeruginosa*, a potential channel for transport of hydrophobic molecules
715 across the outer membrane. *PLoS One* 5:e15016.
- 716 65. Bushell SR, Mainprize IL, Wear MA, Lou H, Whitfield C, Naismith JH. 2013. Wzi Is an
717 Outer Membrane Lectin that Underpins Group 1 Capsule Assembly in *Escherichia coli*.
718 *Structure* 21:844–853.
- 719 66. Shang ES, Exner MM, Summers TA, Martinich C, Champion CI, Hancock RE, Haake DA.
720 1995. The rare outer membrane protein, OmpL1, of pathogenic *Leptospira* species is
721 a heat-modifiable porin. *Infect Immun* 63:3174–81.
- 722 67. Mizuno T, Kageyama M. 1978. Separation and Characterization of the Outer
723 Membrane of *Pseudomonas aeruginosa*. *J Biochem* 84:179–191.
- 724 68. Demirkan I, Walker R. L, Murray R. D, Blowey R. W, Carter S. D. 1999. Serological
725 evidence of spirochaetal infections associated with digital dermatitis in dairy cattle.
726 *Vet J* 157:69–77.
- 727 69. Murray R. D, Downham D. Y, Demirkan I, Carter S. D. 2002. Some relationships
728 between spirochaete infections and digital dermatitis in four UK dairy herds. *Res Vet*
729 *Sci* 73:223–230.

- 730 70. Dhawi A, Hart CA, Demirkan I. 2005. Bovine digital dermatitis and severe virulent
731 ovine foot rot : A common spirochaetal pathogenesis. *Vet J* 169:232–241.
- 732 71. Hashimoto M, Asai Y, Ogawa T. 2003. Treponemal Phospholipids Inhibit Innate
733 Immune Responses Induced by Pathogen-associated Molecular Patterns. *J Biol Chem*
734 278:44205–44213.
- 735 72. Shenker BJ, Listgarten MA, Taichman NS. 1984. Suppression of human lymphocyte
736 responses by oral spirochetes: a monocyte-dependent phenomenon. *J Immunol*
737 132:2039–2045.
- 738 73. Marcatili P, Nielsen MW, Sicheritz-Pontén T, Jensen TK, Schafer-Nielsen C, Boye M,
739 Nielsen M, Klitgaard K. 2016. A novel approach to probe host-pathogen interactions
740 of bovine digital dermatitis, a model of a complex polymicrobial infection. *BMC*
741 *Genomics* 17:987.
- 742 74. Rosander A, Guss B, Frykberg L, Björkman C, Näslund K, Rit Pringle M, Björkman C,
743 Näslund K, Pringle M. 2011. Identification of immunogenic proteins in *Treponema*
744 phagedenis-like strain V1 from digital dermatitis lesions by phage display. *Vet*
745 *Microbiol* 153:315–322.
- 746 75. Pringle M, Bergsten C, Fernström L-L, Höök H, Johansson K-E. 2008. Isolation and
747 characterization of *Treponema phagedenis*-like spirochetes from digital dermatitis
748 lesions in Swedish dairy cattle. *Acta Vet Scand* 50:40.
- 749 76. Stokes JE, Leach KA, Main DCJ, Whay HR. 2012. The reliability of detecting digital
750 dermatitis in the milking parlour. *Vet J* 193:679–684.
- 751 77. Rodriguez-Lainz A, Melendez-Retamal P, Hird DW, Read DH. 1998. Papillomatous

- 752 digital dermatitis in Chilean dairies and evaluation of a screening method. *Prev Vet*
753 *Med* 37:197–207.
- 754 78. Vink WD, Jones G, Johnson WO, Brown J, Demirkan I, Carter SD, French NP. 2009.
755 Diagnostic assessment without cut-offs : Application of serology for the modelling of
756 bovine digital dermatitis infection. *Prev Vet Med* 92:235–248.
- 757 79. Pinne M, Choy HA, Haake DA. 2010. The OmpL37 surface-exposed protein is
758 expressed by pathogenic *Leptospira* during infection and binds skin and vascular
759 elastin. *PLoS Negl Trop Dis* 4:e815.
- 760 80. Oliveira R, Domingos RF, Siqueira GH, Fernandes LG, Souza NM, Vieira ML, de Moraes
761 ZM, Vasconcellos SA, Nascimento ALTO. 2013. Adhesins of *Leptospira interrogans*
762 Mediate the Interaction to Fibrinogen and Inhibit Fibrin Clot Formation In Vitro. *PLoS*
763 *Negl Trop Dis* 7:e2396.
- 764 81. Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. 2003. Matrix-fibrinogen enhances
765 wound closure by increasing both cell proliferation and migration. *Blood* 102:4035–
766 4043.
- 767 82. Krull AC, Cooper VL, Coatney JW, Shearer JK, Gorden PJ, Plummer PJ. 2016. A Highly
768 Effective Protocol for the Rapid and Consistent Induction of Digital Dermatitis in
769 Holstein Calves. *PLoS One* 11:e0154481.
- 770 83. Edwards AM, Dymock D, Woodward MJ, Jenkinson HF. 2003. Genetic relatedness and
771 phenotypic characteristics of *Treponema* associated with human periodontal tissues
772 and ruminant foot disease. *Microbiology* 149:1083–1093.
- 773 84. Levi M, van der Poll T, Büller HR. 2004. Bidirectional Relation Between Inflammation

- 774 and Coagulation. *Circulation* 109:2698–2704.
- 775 85. Ponnuraj K, Bowden MG, Davis S, Gurusiddappa S, Moore D, Choe D, Xu Y, Hook M,
776 Narayana SVL. 2003. A “dock, lock, and latch” Structural Model for a Staphylococcal
777 Adhesin Binding to Fibrinogen. *Cell* 115:217–228.
- 778 86. Bamford C V, Fenno JC, Jenkinson HF, Dymock D. 2007. The chymotrypsin-like
779 protease complex of *Treponema denticola* ATCC 35405 mediates fibrinogen
780 adherence and degradation. *Infect Immun* 75:4364–72.
- 781 87. Berry SL, Read DH, Famula TR, Mongini A, Döpfer D. 2012. Long-term observations on
782 the dynamics of bovine digital dermatitis lesions on a California dairy after topical
783 treatment with lincomycin HCl. *Vet J* 193:654–658.
- 784 88. Farrell DH, Thiagarajan P, Chung DW, Davie EW. 1992. Role of fibrinogen alpha and
785 gamma chain sites in platelet aggregation. *Proc Natl Acad Sci U S A* 89:10729–32.
- 786 89. Hawiger J, Timmons S, Strong DD, Cottrell BA, Riley M, Doolittle RF. 1982.
787 Identification of a region of human fibrinogen interacting with staphylococcal
788 clumping factor. *Biochemistry* 21:1407–13.
- 789 90. Liu C-Z, Shih M-H, Tsai P-J. 2005. ClfA221–550, a fibrinogen-binding segment of
790 *Staphylococcus aureus* clumping factor A, disrupts fibrinogen function. *Thromb*
791 *Haemost* 94:286–94.
- 792 91. Ghosh S, Chakraborty K, Nagaraja T, Basak S, Koley H, Dutta S, Mitra U, Das S. 2011.
793 An adhesion protein of *Salmonella enterica* serovar Typhi is required for pathogenesis
794 and potential target for vaccine development. *Proc Natl Acad Sci U S A* 108:3348–53.
- 795 92. Lithgow K V, Hof R, Wetherell C, Phillips D, Houston S, Cameron CE. 2017. A defined

796 syphilis vaccine candidate inhibits dissemination of *Treponema pallidum* subspecies
797 *pallidum*. *Nat Commun* 8:14273.

798 93. Berry SL, Ertze RA, Read DH HD. 2003. Field evaluation of prophylactic and
799 therapeutic effects of a vaccine against (papillomatous) digital dermatitis of dairy
800 cattle in two California dairies *Proceedings of the 13th International Symposium on*
801 *Ruminant Lameness*. Maribor, Slovenia.

802 94. O'Hagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for
803 vaccines against infectious diseases. *Biomol Eng* 18:69–85.

804 95. Grun JL, Maurer PH. 1989. Different T helper cell subsets elicited in mice utilizing two
805 different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative
806 responses. *Cell Immunol* 121:134–145.

807 96. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. 1999.
808 Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the
809 absence of IL-4- or IL-13-mediated signaling. *J Immunol* 163:6448–54.

810 97. Elliott MK, Alt DP. 2009. Bovine immune response to papillomatous digital dermatitis
811 (PDD)-associated spirochetes is skewed in isolate reactivity and subclass elicitation.
812 *Vet Immunol Immunopathol* 130:256–261.

813

814

815

816

817 **Figure legends.**

818 *Table 2. Each putative treponemal OMP was selected on the basis of predicted β -barrel*
819 *topology by at least one of the β -barrel prediction programs. The results generated by BOMP,*
820 *PRED-TMBB, TMBETA-NET and SPAAN were interpreted in accordance with default cut-off*
821 *values. All four CDS features were predicted to share domain homology with known bacterial*
822 *OMPs.*

823 *Fig. 1. The four putative β barrel-outer membrane proteins (a-d) were structurally modelled*
824 *using I-TASSER. A lateral view of the top-ranking ribbon model, as determined by the C-score,*
825 *is shown, with β -sheet depicted in blue and α -helix depicted in red.*

826 *Table 3. The amino acid sequence of each putative OMP was submitted to I-TASSER for 3D*
827 *structural modelling and Protein Databank (PDB) structural analogue detection. ¹C-Score: A*
828 *confidence score for estimating the quality of predicted models.*

829 *Fig. 2. Gel A, C5N99_02965; Gel B, C5N99_10335; Gel C, DYQ05_06810. Gels A, B and C: 1,*
830 *Wide-range MW marker (kDa); 2, unheated sample; 3, heated sample. The heat-modified*
831 *(unfolded) forms of the proteins are distinguished from the unmodified (folded) forms by the*
832 *addition of an asterisk (*). Panel C: lane between marker and sample contained a wash*
833 *fraction and has been removed for brevity.*

834 *Fig. 3. CD spectra of proteins encoded by a) C5N99_10335, b) C5N99_02965, c) DYQ05_06810,*
835 *d) DYQ05_13425 and e) *L. interrogans* OmpL1 are shown. Far-UV CD spectra are presented as*
836 *an average of three scans recorded from 190 to 260 nm. φ , molar ellipticity.*

837

838 *Fig. 4. Serological assessment of the IgG1 and IgG2 response to putative treponemal OMPs by*
839 *ELISA. Error bars: standard error of the mean. Non-exp., Non-exposed; DD exp., digital*
840 *dermatitis-exposed. Asterisks (*) indicates a significant difference in IgG seroreactivity relative*
841 *to control sera as determined by Mann-Whitney U test (* P<0.05, ** P<0.005).*

842 *Fig. 5. Immobilised ECM component binding screens of four putative β -barrel OMPs and the*
843 *positive control protein (OmpL1). Bars represent the mean OD of three independent*
844 *experiments. Error bars: standard error of the mean. Asterisks (*) indicate a significant*
845 *difference in binding compared to the negative control protein, BSA, as determined by one-*
846 *way ANOVA and the Dunnett post-test (* P<0.05, **P<0.005, ***P<0.001).*

847 *Fig. 6. Binding affinity curves of the four putative β -barrel OMPs to bovine fibrinogen. Graph*
848 *A, putative OMPs from *T. medium*; Graph B, putative OMPs from *T. pedis*. Data points*
849 *represent the mean OD of replicate readings. Error bars: standard error of the mean.*

850 *Fig. 7. Specific binding interactions between the recombinant proteins and the α , β and γ*
851 *chains of bovine fibrinogen, using monoclonal Anti-polyHistidine antibody as the probe.*

852 *Fig 8. The serological IgG1 and IgG2 response to four treponemal putative OMPs was assessed*
853 *in BDD-naïve calves (n=2). The mean OD of both immunised calves is shown. Error bars:*
854 *standard error of the mean.*

855

856

857

858

859

860

861

862 **Figures and Tables.**

863 **Table 1. Primers used to amplify putative OMP genes for recombinant expression.**

Putative OMP locus tag	<i>Treponema</i> phylogroup	Primer sequence (5'-3')	Predicted band size (kb)	Predicted mass (Kda)
C5N99_10335	<i>T. medium</i>	Forward: CACCGATGGGGTCGATTTTTCG Reverse: CTACAGCTTAAAAGCGATCC	0.7	27.1
C5N99_02965	<i>T. medium</i>	Forward: CACCCAGGAAGAAGGAGCAGAGG Reverse: AGAGATACCCATTAGTTGTTG	0.9	35.0
DYQ05_13425	<i>T. pedis</i>	Forward: CACCTTAAGCGATATTTTCAGGCGATG Reverse: TTACAGCTTCCATGCAATACC	0.8	29.8
DYQ05_06810	<i>T. pedis</i>	Forward: CACCGCAAAGACTATCGGTCTTAATTG Reverse: TTAATAAATAAAGCTTAAACCCGC	0.9 0.6	22.1
OmpL1	<i>L. interrogans</i>	Forward: CACCAAACATATGCAATTGTAGGATTG Reverse: TTAGAGTTCGTGTTTATAACCG	0.8	31.0

864

865 **Table 2. Bioinformatic analysis of four putative treponemal OMPs.**

Putative OMP	<i>Treponema</i> phylogroup	Signal peptide cleavage site	β -barrel and adhesin prediction				Homologous domain search		
			BOMP	PRED-TMBB	TMBETA-NET	SPAAN	PDB Top Hit (% probability; E-value)	Function	Ref.
C5N99_02965	<i>T. medium</i>	YES (20/21; LSA/QE)	YES	NO	YES	YES	OmpU (57.16; 120)	OM Porin	(58)
C5N99_10335	<i>T. medium</i>	YES (21/22; VFS/DG)	YES	YES	YES	YES	OmpA (97.71; 6.1e-5)	OM Porin/adhesin	(59, 60)
DYQ05_13425	<i>T. pedis</i>	YES (21/22; AFN/LS)	NO	YES	YES	YES	OmpA (98.07; 4.9e-6)	OM Porin/adhesin	(59, 60)
DYQ05_06810	<i>T. pedis</i>	YES (22/22; LSA/QT)	YES	YES	YES	YES	OprF (97.32; 0.0014)	OM porin	(61)

866

867


868

869

870

871

872

873 *Figure 1. Prediction of the treponemal putative OMP 3-dimensional structure*

874

875

876 *Table 3. I-TASSER structural modelling of the treponemal OMPs: A summary of results.*

Putative OMP	C-score ¹	Predicted topology	PDB Structural analog (bacterial species)	Structural analog function	Ref.
C5N99_10335	3.98	8-stranded β -barrel	OmpT (<i>E. coli</i>)	Protease	(62)
C5N99_02965	2.73	β -solenoid barrel	serine-rich repeat protein (<i>Lactobacillus reuterii</i>)	Cell adhesion	(63)
DYQ05_13425	4.07	8-stranded β -barrel	OprG (<i>Pseudomonas aeruginosa</i>)	Porin	(64)
DYQ05_06810	2.73	8-stranded β -barrel	OmpA (<i>E. coli</i>)	Porin	(65)

877


878

879

880

881


882 Figure 2. Heat-modifiability of C5N99_10335, C5N99_02965 and DYQ05_06810.



883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902

903

904 Fig 3. Determination of protein fold state using far UV Circular Dichroism (CD).



905

906

907

908


909

910

911

912

913 Fig 4. Determination by ELISA of the serological response to four putative OMPs in BDD-
 914 positive adult Holstein-Friesian dairy cattle.



915

916


917

918

919

920

921 Fig 5. Analysis of the attachment of treponemal putative OMPs to ECM components.




922

923

924

925

926 Fig. 6. Binding affinity curves of the four putative β -barrel OMPs to bovine fibrinogen.



927

928

929 Table 4. Binding interactions between the putative recombinant OMPs and bovine
930 fibrinogen.


931

OMP	Dissociation Constant (K_D)
C5N99_02965	0.3370 ± 0.09753
DYQ05_13425	0.7180 ± 0.08743
DYQ05_16810	1.024 ± 0.2946
OmpL1	0.3669 ± 0.04328 (0.223 ± 0.063 (47))

932

933 Fig. 7. Far western blotting analysis of the treponemal recombinant OMP-Bovine fibrinogen


934 binding interactions.



935

936

937 Fig. 8. Serological IgG1 and IgG2 response to immunisation with four recombinant treponemal
 938 putative OMPs.



939
 940
 941

942 Table 5. Fold-change in calf seroreactivity to the inoculated treponemal recombinant putative
 943 OMPs.

944

<i>Antigen</i>	<i>IgG1 Fold-change (day 28 post-immunisation)</i>	<i>IgG2 Fold-change (day 28 post immunisation)</i>
C5N99_10335	2.37	1.66
C5N99_02965	4.34	3.58
DYQ05_13425	7.44	9.10
DYQ05_06810	5.42	6.00

945
 946
 947
 948
 949
 950
 951
 952
 953